Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 1 | 1 | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | — | 1 | 1 | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | — | 1 | 1 | — | — | 1 |
B-cell lymphoma | D016393 | — | — | — | 1 | 1 | — | — | 1 |
Drug common name | Odronextamab |
INN | odronextamab |
Description | Odronextamab (REGN1979) is a CD20 x CD3 bispecific monoclonal antibody that is developed by Regeneron Pharmaceuticals for B-cell non-Hodgkin lymphoma.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4298084 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 8R5CM46UIO (ChemIDplus, GSRS) |